Platelet aggregation signaling

Platelet aggregation signaling is a complex biological pathway essential for primary hemostasis and the pathological development of arterial thrombosis (Reactome R-HSA-76002). The process is initiated when vascular injury exposes subendothelial collagen and von Willebrand factor, which are recognized by platelet receptors such as Glycoprotein VI and the GPIb-V-IX complex (StatPearls, "Physiology, Platelet Activation"). This initial adhesion triggers intracellular signaling cascades involving phospholipase C and calcium mobilization, leading to the release of secondary agonists like adenosine diphosphate (ADP) and thromboxane A2 (Circulation Research, "Platelet Signaling"). These agonists act in an autocrine and paracrine fashion via G protein-coupled receptors, such as P2Y12 and TP, to amplify the activation signal. The final common pathway of platelet aggregation is the "inside-out" signaling that activates the integrin alpha-IIb/beta-3 (GPIIb/IIIa) receptor, enabling it to bind bivalent fibrinogen and cross-link adjacent platelets into a stable thrombus (PubMed, PMID: 20508184). Dysregulation of this signaling is a primary cause of myocardial infarction and ischemic stroke, making it a major focus for pharmacological intervention. Antiplatelet drugs, including COX-1 inhibitors (Aspirin), P2Y12 antagonists (Clopidogrel), and GPIIb/IIIa inhibitors (Abciximab), target specific nodes within this signaling network to prevent occlusive vascular events (NIH, "Antiplatelet Agents").

Other names

Platelet activation pathwayThrombocyte aggregation signalingHemostatic signaling cascade

Antiplatelet drugs modulate this signaling pathway by inhibiting specific receptors (e.g., P2Y12, PAR-1), enzymes (e.g., COX-1), or integrins (e.g., GPIIb/IIIa) to prevent platelet activation and aggregation (Circulation, 2019).